Molecular Weight(MW): 146.14
L-Glutamine (Gln) is one of the 20 amino acids encoded by the standard genetic code and also a major respiratory fuel and substrate for nucleic acid synthesis in mammalian intestinal cells.
Purity & Quality Control
|Description||L-Glutamine (Gln) is one of the 20 amino acids encoded by the standard genetic code and also a major respiratory fuel and substrate for nucleic acid synthesis in mammalian intestinal cells.|
L-Glutamine (0.2 and 2 mM) but not D-Gln inhibits the generation of L-Arg by both Arg-depleted and nondepleted endothelial cells. L-Glutamine also inhibits the conversion of L-[14C]Cit to L-[14C]Arg by Arg-depleted endothelial cells. L-Glutamine interferes with the conversion of L-Cit to L-Arg probably by acting on argininosuccinate synthetase rather than argininosuccinate lyase. L-Glutamine also inhibits the generation of L-Arg by the monocyte-macrophage cell line J774 but has no effect on the conversion of L-Cit to L-Arg by these cells.  L-Glutamine metabolism stimulates Na+-H+exchange of acid-loaded porcine enterocytes by a mechanism not requiring activation of PKC.  L-Glutamine (0.2 mM and 2 mM) but not D-glutamine (2 mM), L-glutamic acid (2 mM) or ammonium chloride (1 mM) also inhibits the generation of L-arginine in endothelial cells.  L-glutamine promotes chromatin condensation and formation of crescent-like structures in the nucleus of murine primary microglia as well as of the microglial cell-line BV-2. 
|In vivo||L-Glutamine at 0.5, 2 and 5 mM dose-dependently reduces H(2)O(2)- or LPS-induced cell death by 14%, 54% and 95%. L-Glutamine increases Glutamine concentrations in small-intestinal lumen and plasma, reduces intestinal expression of Toll-like receptor-4, active caspase-3 and NFkB, ameliorates intestinal injury, decreases rectal temperature, and enhanced growth performance in LPS-challenged piglets. |
-  Sessa WC, et al. Proc Natl Acad Sci U S A,?990, 87(21), 8607-8611.?
-  Rhoads JM, et al. Am J Physiol,?994, 266(5 Pt 1), G828-838.
-  Hecker M, et al. Br J Pharmacol,?990, 101(2), 237-239.
|In vitro||Water||29 mg/mL (198.43 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02053350||Terminated||Clostridium Difficile Infection||University of Virginia||April 2015||Phase 2|
|NCT02215083||Withdrawn||Peripheral Neuropathy||Eastern Regional Medical Center|TSPC America Inc.||August 2014||Phase 1|
|NCT03015077||Completed||Head and Neck Cancer||Kaohsiung Medical University Chung-Ho Memorial Hospital||July 2014||Not Applicable|
|NCT01832636||Completed||Malnutrition|Environmental Enteropathy|Diarrhea||Children''s Hospital Medical Center Cincinnati|Universidade Federal do Ceara||October 2013||Phase 3|
|NCT01353638||Terminated||End Stage Renal Disease||Christoph Aufricht|Medical University of Vienna||April 2011||Phase 1|Phase 2|
|NCT01250782||Unknown status||Trauma ICU Patients||Hospital Universitari Son Dureta||October 2010||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.